Core Viewpoint - Ruili Medical Beauty (02135) anticipates a decline in revenue and an increase in losses for the six months ending June 30, 2025, compared to the same period in 2024 [1] Financial Performance - Expected revenue for the six months ending June 30, 2025, is approximately RMB 85 million, down from RMB 117 million for the same period in 2024 [1] - Anticipated loss attributable to the parent company for the six months ending June 30, 2025, is approximately RMB 8 million, compared to a loss of RMB 2 million for the same period in 2024 [1] Reasons for Loss - The board attributes the loss primarily to intense market competition, resulting in a total revenue decline of approximately RMB 32 million compared to the same period in 2024 [1] - The medical beauty services and medical beauty management consulting services segment experienced an operational loss of approximately RMB 2 million during the reporting period [1] - Share-based payment expenses during the reporting period amounted to approximately RMB 1 million [1] - Increased investment in research and development for medical device products, particularly in the indirect non-wholly owned subsidiary Suzhou Ruichuan Biomedical Technology Co., Ltd., with management and R&D expenses of approximately RMB 1 million [1]
瑞丽医美(02135)发盈警，预期中期股东应占亏损约800万元 同比扩大